Reported Earlier, SAB Biotherapeutics Prices 19,324,677 Common Shares At $3.85 And 2,753,246 Pre-Funded Warrants At $3.8499 In $85M Public Offering

Benzinga Newsdesk www.benzinga.com Neutral 94.0%